Atea Pharmaceuticals (NASDAQ:AVIR) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of direct‐acting antiviral therapies. Founded in 2014 and headquartered in Boston, Massachusetts, Atea’s mission is to develop oral treatments that address serious viral infections. The company leverages its expertise in medicinal chemistry and virology to advance a pipeline of small‐molecule drug candidates designed to inhibit viral replication and mitigate disease progression.
The lead program in Atea’s pipeline is AT-527, an orally administered nucleotide analog initially developed for chronic hepatitis C virus (HCV) infection and later evaluated in phases of clinical trials for COVID-19 and other respiratory viral diseases. Preclinical and early clinical data have shown that AT-527 exhibits potent antiviral activity and a favorable safety profile. In addition, Atea is progressing AT-752, a broad‐spectrum oral antiviral candidate targeting flaviviruses such as dengue and West Nile virus. The company’s research efforts underscore its commitment to addressing both emerging and endemic viral threats.
Atea maintains a global footprint, with research and development operations located in Boston, Massachusetts, and Shanghai, China. This dual‐site structure enables the company to tap into international scientific talent and streamline clinical trial execution across multiple regions. Atea collaborates with academic institutions, contract research organizations and global health initiatives to support the advancement of its antiviral programs and foster access to new therapies in regions disproportionately affected by viral epidemics.
Under the leadership of President and Chief Executive Officer Jay Siegel, Atea has built a management team with extensive experience in virology, drug development and regulatory strategy. The company’s board of directors and scientific advisory committee include seasoned professionals who have led successful antiviral programs at both large pharmaceutical companies and biotech startups. Atea continues to prioritize rigorous clinical development, regulatory engagement and strategic partnerships as it seeks to bring novel antiviral medicines to patients worldwide.
